Company Overview: SHPG

Upcoming Projects (SHPG)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (SHPG)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (SHPG)

Comparing Roche’s emicizumab (ACE910) recent Phase 3 HAVEN 1 and 2 results to Bioverativ’s FDA approved Eloctate and Alprolix in the treatment of Hemophilia
Tickers: RHHBY, BIVV, SHPG
Execute By: Aug 18, 2017

Upcoming & Overdue Catalysts (SHPG)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (SHPG)

Shire's (SHPG) Cinryze Approved for Expanded Indication in Europe to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Pediatric Patients with HAE
Ticker: SHPG
Occurred on: Mar 16, 2017
CHMP Recommends EU Conditional Marketing Authorization for NATPAR (NATPARA in the US)
Ticker: SHPG
Occurred on: Feb 24, 2017
Shire (SHPG) Phase 1b Results Evaluating Lanadelumab in Treatment of Hereditary Angioedema (HAE) Published in the New England Journal of Medicine
Ticker: SHPG
Occurred on: Feb 23, 2017
Resubmission of FDA Filing for SHP465 Projected Late 2016
Ticker: SHPG
Occurred on: Jan 19, 2017
Topline results of Phase 3 investigational study of VONVENDI
Ticker: SHPG
Occurred on: Dec 02, 2016
Shire (SHPG) Begins Commercial Launch of Cuvitru in U.S for Adult and Pediatric Patients with Primary Immunodeficiency
Ticker: SHPG
Occurred on: Nov 16, 2016
Phase 2b study data of SHP610 the treatment of the rare lysosomal storage disease, SanFilippo A, due mid-2016
Ticker: SHPG
Occurred on: Nov 01, 2016
Shire (SHPG) Announces Phase 2 Data Analyzing Maribavir in Patients with Cytomegalovirus (CMV) Infection Undergoing Hematopoietic Stem Cell Transplant (HSCT) or Solid Organ Transplant
Ticker: SHPG
Occurred on: Oct 27, 2016
Shire's (SHPG) ONIVYDE Approved by European Commission for Metastatic Adenocarcinoma
Ticker: SHPG
Occurred on: Oct 18, 2016
U.S District Court Rules Against Shire (SHPG) in Patent Infringement Case Against Cadila Over Ulcerative Colitis Med Lialda
Tickers: SHPG, Zydus Cadila
Occurred on: Sep 16, 2016
Shire's (SHPG) CUVITRU Recieves FDA Approval for the Treatment of Primary Immunodeficiency In Over 300 Genetic Disorders
Ticker: SHPG
Occurred on: Sep 14, 2016
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
Ticker: SHPG
Occurred on: Aug 01, 2016
Shire’s SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults who have Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
Ticker: SHPG
Occurred on: Jul 29, 2016
Merrimack Announces ONIVYDE Regimen for Pancreatic Cancer Receives Positive CHMP Opinion in European Union
Tickers: MACK, SHPG
Occurred on: Jul 25, 2016
Shire launches pediatric indication for immunodeficiency treatment HyQvia in Europe
Ticker: SHPG
Occurred on: Jul 21, 2016
Chronos has acquired three pre-clinical programmes from a subsidiary of Shire PLC
Tickers: SHPG, Chronos
Occurred on: Jul 20, 2016
Shire reinforces commitment in Hematology with robust data presented at international congress of the World Federation of Hemophilia
Ticker: SHPG
Occurred on: Jul 19, 2016
FDA Approves Shire’s Xiidra (lifitegrast ophthalmic solution) 5% – The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
Ticker: SHPG
Occurred on: Jul 11, 2016
U.S. FDA Acknowledges Receipt of Resubmission of Shire’s New Drug Application for Lifitegrast for Dry Eye Disease in Adults; New FDA action date set for July 22, 2016
Ticker: SHPG
Occurred on: Jul 11, 2016
Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
Ticker: SHPG
Occurred on: Jun 30, 2016
Phase 2 data expected to be released for SHP607 study on retinopathy of prematurity
Ticker: SHPG
Occurred on: Jun 30, 2016
Phase 3 Study of SHP465 in Adults with ADHD Due End of Q1 of 2016
Ticker: SHPG
Occurred on: Jun 29, 2016
Shire Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults with ADHD
Ticker: SHPG
Occurred on: Jun 29, 2016
Shire Receives FDA Breakthrough Therapy Designation for SHP621 and SHP625, Investigational Products for Rare Gastrointestinal Conditions
Ticker: SHPG
Occurred on: Jun 13, 2016
Shire acquires Baxalta for $45.57 per share ($32B). The deal represents a 13.9% premium to Baxalta's closing price
Tickers: SHPG, BXLT
Occurred on: Jun 03, 2016
Firazyr HAE Japan Top-line data due Q2 of 2016
Ticker: SHPG
Occurred on: Apr 15, 2016
Shire Announces Positive Results of SHP465 Safety and Efficacy Study in Children and Adolescents with ADHD
Ticker: SHPG
Occurred on: Apr 04, 2016
Shire Expected to Initiate Phase 3 Trial of CINRYZE (SHP616) to Treat Children with Angioedema Attacks in mid-2016
Ticker: SHPG
Occurred on: Mar 10, 2016
Shire and partner Shionogi file NDA in Japan for ADHD treatment
Ticker: SHPG
Occurred on: Feb 10, 2016

Strategic Initiatives (SHPG)

Takeda (TKPYY) Nearing in on Deal to Buy Shire (SHPG) for $64 Billion
Tickers: TKPYY, SHPG
Announcement Date: May 07, 2018
Shire and NanoMedSyn Enter Into Research Agreement for Potential Lysosomal Storage Disorder Treatment
Tickers: SHPG, NanoMedSyn
Announcement Date: Mar 26, 2018
Baxalta (SHPG) Pays $10.3MM to Return Blood Cancer Candidate Pacritinib to CTI BioPharma (CTIC)
Tickers: CTIC, SHPG, Baxalta
Announcement Date: Oct 24, 2016
Shire (SHPG) Extends Kamada's (KMDA) GLASSIA Supply Agreement Through 2020
Tickers: KMDA, SHPG
Announcement Date: Oct 06, 2016

SHPG Overview